Logo image of IONS

IONIS PHARMACEUTICALS INC (IONS) Stock Fundamental Analysis

USA - NASDAQ:IONS - US4622221004 - Common Stock

73.07 USD
+0.68 (+0.94%)
Last: 10/16/2025, 8:00:02 PM
73.1263 USD
+0.06 (+0.08%)
After Hours: 10/16/2025, 8:00:02 PM
Fundamental Rating

3

Overall IONS gets a fundamental rating of 3 out of 10. We evaluated IONS against 536 industry peers in the Biotechnology industry. IONS has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, IONS is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

IONS had negative earnings in the past year.
IONS had a negative operating cash flow in the past year.
In the past 5 years IONS always reported negative net income.
The reported operating cash flow has been mixed in the past 5 years: IONS reported negative operating cash flow in multiple years.
IONS Yearly Net Income VS EBIT VS OCF VS FCFIONS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M -400M 600M

1.2 Ratios

Looking at the Return On Assets, with a value of -8.99%, IONS belongs to the top of the industry, outperforming 84.89% of the companies in the same industry.
IONS has a Return On Equity of -42.46%. This is in the better half of the industry: IONS outperforms 70.52% of its industry peers.
Industry RankSector Rank
ROA -8.99%
ROE -42.46%
ROIC N/A
ROA(3y)-12.67%
ROA(5y)-11.54%
ROE(3y)-72.98%
ROE(5y)-56.49%
ROIC(3y)N/A
ROIC(5y)N/A
IONS Yearly ROA, ROE, ROICIONS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 -40 -60 -80

1.3 Margins

Looking at the Gross Margin, with a value of 98.89%, IONS belongs to the top of the industry, outperforming 97.57% of the companies in the same industry.
IONS's Gross Margin has been stable in the last couple of years.
IONS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 98.89%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.08%
GM growth 5Y-0.24%
IONS Yearly Profit, Operating, Gross MarginsIONS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50

More info and screens

3

2. Health

2.1 Basic Checks

IONS does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, IONS has more shares outstanding
Compared to 5 years ago, IONS has more shares outstanding
Compared to 1 year ago, IONS has an improved debt to assets ratio.
IONS Yearly Shares OutstandingIONS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
IONS Yearly Total Debt VS Total AssetsIONS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

2.2 Solvency

IONS has an Altman-Z score of 2.60. This is not the best score and indicates that IONS is in the grey zone with still only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 2.60, IONS is in the better half of the industry, outperforming 66.98% of the companies in the same industry.
IONS has a Debt/Equity ratio of 0.99. This is a neutral value indicating IONS is somewhat dependend on debt financing.
IONS's Debt to Equity ratio of 0.99 is on the low side compared to the rest of the industry. IONS is outperformed by 75.93% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.99
Debt/FCF N/A
Altman-Z 2.6
ROIC/WACCN/A
WACC8.95%
IONS Yearly LT Debt VS Equity VS FCFIONS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M 1B

2.3 Liquidity

IONS has a Current Ratio of 2.87. This indicates that IONS is financially healthy and has no problem in meeting its short term obligations.
IONS has a Current ratio of 2.87. This is in the lower half of the industry: IONS underperforms 65.49% of its industry peers.
IONS has a Quick Ratio of 2.86. This indicates that IONS is financially healthy and has no problem in meeting its short term obligations.
IONS has a worse Quick ratio (2.86) than 63.81% of its industry peers.
Industry RankSector Rank
Current Ratio 2.87
Quick Ratio 2.86
IONS Yearly Current Assets VS Current LiabilitesIONS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B 2.5B

More info and screens

5

3. Growth

3.1 Past

IONS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 26.98%, which is quite impressive.
IONS shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 16.05%.
IONS shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -8.88% yearly.
EPS 1Y (TTM)26.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%255.56%
Revenue 1Y (TTM)16.05%
Revenue growth 3Y-4.54%
Revenue growth 5Y-8.88%
Sales Q2Q%100.69%

3.2 Future

Based on estimates for the next years, IONS will show a very strong growth in Earnings Per Share. The EPS will grow by 27.00% on average per year.
The Revenue is expected to grow by 30.89% on average over the next years. This is a very strong growth
EPS Next Y14.49%
EPS Next 2Y-3.26%
EPS Next 3Y12.78%
EPS Next 5Y27%
Revenue Next Year38.57%
Revenue Next 2Y20.08%
Revenue Next 3Y28.34%
Revenue Next 5Y30.89%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
IONS Yearly Revenue VS EstimatesIONS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 1B 2B 3B 4B
IONS Yearly EPS VS EstimatesIONS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 -2 4 6 8

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

IONS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IONS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IONS Price Earnings VS Forward Price EarningsIONS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IONS Per share dataIONS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

IONS's earnings are expected to grow with 12.78% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-3.26%
EPS Next 3Y12.78%

More info and screens

0

5. Dividend

5.1 Amount

IONS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IONIS PHARMACEUTICALS INC

NASDAQ:IONS (10/16/2025, 8:00:02 PM)

After market: 73.1263 +0.06 (+0.08%)

73.07

+0.68 (+0.94%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)07-30 2025-07-30/bmo
Earnings (Next)11-04 2025-11-04/bmo
Inst Owners108.22%
Inst Owner Change0.2%
Ins Owners0.73%
Ins Owner Change-2.3%
Market Cap11.65B
Analysts81.94
Price Target74.51 (1.97%)
Short Float %7.57%
Short Ratio4.7
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)138.96%
Min EPS beat(2)18.36%
Max EPS beat(2)259.57%
EPS beat(4)4
Avg EPS beat(4)84.95%
Min EPS beat(4)18.36%
Max EPS beat(4)259.57%
EPS beat(8)8
Avg EPS beat(8)62.05%
EPS beat(12)11
Avg EPS beat(12)45.8%
EPS beat(16)13
Avg EPS beat(16)59.56%
Revenue beat(2)2
Avg Revenue beat(2)26.7%
Min Revenue beat(2)3.26%
Max Revenue beat(2)50.14%
Revenue beat(4)4
Avg Revenue beat(4)29.02%
Min Revenue beat(4)0.96%
Max Revenue beat(4)61.73%
Revenue beat(8)7
Avg Revenue beat(8)29.7%
Revenue beat(12)10
Avg Revenue beat(12)22.78%
Revenue beat(16)12
Avg Revenue beat(16)20.42%
PT rev (1m)21.57%
PT rev (3m)28.08%
EPS NQ rev (1m)0.5%
EPS NQ rev (3m)-32.29%
EPS NY rev (1m)-1.16%
EPS NY rev (3m)17.37%
Revenue NQ rev (1m)0.33%
Revenue NQ rev (3m)-18.09%
Revenue NY rev (1m)-0.23%
Revenue NY rev (3m)13.69%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 12.34
P/FCF N/A
P/OCF N/A
P/B 18.44
P/tB 18.44
EV/EBITDA N/A
EPS(TTM)-1.84
EYN/A
EPS(NY)-3.24
Fwd EYN/A
FCF(TTM)-1.82
FCFYN/A
OCF(TTM)-1.45
OCFYN/A
SpS5.92
BVpS3.96
TBVpS3.96
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -8.99%
ROE -42.46%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 98.89%
FCFM N/A
ROA(3y)-12.67%
ROA(5y)-11.54%
ROE(3y)-72.98%
ROE(5y)-56.49%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.08%
GM growth 5Y-0.24%
F-Score5
Asset Turnover0.32
Health
Industry RankSector Rank
Debt/Equity 0.99
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 929.54%
Cap/Sales 6.3%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.87
Quick Ratio 2.86
Altman-Z 2.6
F-Score5
WACC8.95%
ROIC/WACCN/A
Cap/Depr(3y)219.39%
Cap/Depr(5y)190.33%
Cap/Sales(3y)4.04%
Cap/Sales(5y)3.68%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)26.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%255.56%
EPS Next Y14.49%
EPS Next 2Y-3.26%
EPS Next 3Y12.78%
EPS Next 5Y27%
Revenue 1Y (TTM)16.05%
Revenue growth 3Y-4.54%
Revenue growth 5Y-8.88%
Sales Q2Q%100.69%
Revenue Next Year38.57%
Revenue Next 2Y20.08%
Revenue Next 3Y28.34%
Revenue Next 5Y30.89%
EBIT growth 1Y26.58%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year31.51%
EBIT Next 3Y14.11%
EBIT Next 5YN/A
FCF growth 1Y40.61%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y49.45%
OCF growth 3YN/A
OCF growth 5YN/A